The company develops new therapies intended to improve outcomes in patients suffering from life-threatening diseases.
La Jolla Research and Development vice-president and an inventor on the allowed patent application James Rolke said the company is happy to have received these additional claims covering aqueous solutions of modified pectin with limited molecular weight restrictions for the treatment of chronic inflammation.
"These newly allowed claims expand our proprietary position for the use of modified pectin as a treatment for organ diseases that result from chronic inflammation," Rolke said.
Property portfolio of the company includes several issued and pending patents for the treatment of chronic inflammation.
The company said that these issued and pending patents provide or will provide proprietary coverage for its pectin-based drugs, GCS-100 and LJPC-1010, as well as other modified pectin materials, including all modified pectins currently in clinical development.
Pectins are high molecular weight, complex polysaccharides that can be obtained from multiple sources all of which share a common basic structure comprising a block co-polymer of 1,4-linked galacturonic acid and 1,2-linked rhamnose with side branches of either 1,4-linked ß-D-galactose or 1,5-a-linked L-arabinose.
Additionally, some portion of the galacturonic acid backbone can be esterified or exist as the uronic acid salt.